drug	genes	question	long_answer	answer	llm_answer	score
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 positive for HLA-B with regards to taking abacavir? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Abacavir is not recommended	Avoid	Avoid	True
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 negative for HLA-B with regards to taking abacavir? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use abacavir per standard dosing guidelines	Unchanged	Avoid	False
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 positive for HLA-B with regards to taking allopurinol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Allopurinol is contraindicated	Avoid	Avoid	True
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 negative for HLA-B with regards to taking allopurinol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use allopurinol per standard dosing guidelines	Unchanged	Unchanged	True
amikacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Avoid	True
amikacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
amikacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Unchanged	True
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aminosalicylic acid? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Unchanged	True
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aminosalicylic acid? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aminosalicylic acid? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	No response (safety filter)	False
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Alter dose	No response (safety filter)	False
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	Alter dose	True
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Avoid	Alter dose	False
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Avoid	No response (safety filter)	False
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Avoid	Alter dose	False
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	No response (safety filter)	False
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aspirin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
aspirin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aspirin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Unchanged	True
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aspirin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Poor Metabolizer for UGT1A1 with regards to taking atazanavir? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).	Avoid	No response (safety filter)	False
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Indeterminate for UGT1A1 with regards to taking atazanavir? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Avoid	False
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Normal Metabolizer for UGT1A1 with regards to taking atazanavir? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	Unchanged	No response (safety filter)	False
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Intermediate Metabolizer for UGT1A1 with regards to taking atazanavir? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	Unchanged	No response (safety filter)	False
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking atomoxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	Alter dose	No response (safety filter)	False
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking atomoxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Alter dose	No response (safety filter)	False
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking atomoxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.	Alter dose	No response (safety filter)	False
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking atomoxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Avoid	False
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking atomoxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking atorvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Alter dose	True
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking atorvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Alter dose: consider starting with lower starting dose	False
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking atorvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Avoid	False
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking atorvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Alter dose	False
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking atorvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Unchanged	True
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking atorvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Alter dose	Alter dose	True
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Alter dose	No response (safety filter)	False
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	Alter dose	No response (safety filter)	False
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Avoid	Alter dose	False
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Avoid	Unchanged	False
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	Avoid	Alter dose	False
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and No Result for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Unchanged	Alter dose	False
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Unchanged	Alter dose	False
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is No Result for TPMT and Indeterminate for NUDT15 with regards to taking azathioprine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	NUDT15 phenotype could not be assigned based on genotyping performed and no TPMT genotype is available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Unchanged	Alter dose	False
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking capecitabine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	Alter dose	No response (safety filter)	False
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking capecitabine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	Alter dose	No response (safety filter)	False
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking capecitabine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Avoid	Avoid	True
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for DPYD with regards to taking capecitabine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.	Avoid	Alter dose	False
capecitabine	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking capecitabine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	Unchanged	No response (safety filter)	False
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 positive for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.	Avoid	Avoid	True
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is carbamazepine-naïve, do not use carbamazepine.	Avoid	Avoid	True
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 positive for HLA-B with regards to taking carbamazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is carbamazepine-naïve, do not use carbamazepine.	Avoid	Avoid	True
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use carbamazepine per standard dosing guidelines.	Unchanged	Unchanged	True
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use carbamazepine per standard dosing guidelines.	Unchanged	Avoid	False
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use carbamazepine per standard dosing guidelines.	Unchanged	Avoid	False
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking celecoxib? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Alter dose	Alter dose	True
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking celecoxib? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Alter dose	Alter dose	True
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking celecoxib? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking celecoxib? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking celecoxib? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloramphenicol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloramphenicol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloramphenicol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloroquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
chloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloroquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
chloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloroquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ciprofloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ciprofloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Unchanged	True
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ciprofloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
citalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking citalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	Avoid	Alter dose	False
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking citalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Avoid	Alter dose	False
citalopram	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking citalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Avoid	Avoid	True
citalopram	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking citalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose	Unchanged	Alter dose	False
citalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking citalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking citalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Unchanged	Alter dose	False
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Alter dose	Unchanged	False
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and No Result for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Alter dose	Unchanged	False
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	No response (safety filter)	False
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Avoid	Avoid	True
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Avoid	No response (safety filter)	False
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Avoid	No response (safety filter)	False
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	No response (safety filter)	False
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking clopidogrel? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.	Avoid	Alter dose	False
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking clopidogrel? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	Avoid	No response (safety filter)	False
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking clopidogrel? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	Avoid	Alter dose	False
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking clopidogrel? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If considering clopidogrel, use at standard dose (75 mg/day)	Unchanged	No response (safety filter)	False
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking codeine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Avoid	Avoid	True
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking codeine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Avoid	Avoid	True
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking codeine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Avoid	Avoid	True
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking codeine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use codeine label recommended age- or weight-specific dosing.	Unchanged	No response (safety filter)	False
codeine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking codeine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.	Unchanged	No response (safety filter)	False
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking codeine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use codeine label recommended age- or weight-specific dosing.	Unchanged	No response (safety filter)	False
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dapsone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dapsone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
dapsone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dapsone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
dapsone	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking dapsone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Alter dose	False
dapsone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dapsone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking desflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Unchanged	True
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Alter dose	Avoid	False
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Alter dose	Alter dose	True
desipramine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Alter dose	Alter dose	True
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Avoid	Alter dose	False
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Avoid	No response (safety filter)	False
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Avoid	Avoid	True
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose	Unchanged	Alter dose	False
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose	Unchanged	Unchanged	True
desipramine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking desipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Avoid	False
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Alter dose	Avoid	False
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy."	Alter dose	Unchanged	False
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Alter dose	Alter dose	True
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking dexlansoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Avoid	True
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Unchanged	True
dimercaprol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dimercaprol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Avoid	False
dimercaprol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dimercaprol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dimercaprol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	No response (safety filter)	False
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Alter dose	Unchanged	False
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	Alter dose	True
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Avoid	Alter dose	False
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Avoid	Alter dose	False
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Avoid	Avoid	True
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking doxepin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking doxorubicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
doxorubicin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking doxorubicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Alter dose	False
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking doxorubicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Alter dose	False
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 with regards to taking efavirenz? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider initiating efavirenz with decreased dose of 400 or 200 mg/day	Alter dose	Avoid	False
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 with regards to taking efavirenz? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider initiating efavirenz with decreased dose of 400 mg/day	Alter dose	Avoid	False
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 with regards to taking efavirenz? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate efavirenz with standard dosing (600 mg/day)	Unchanged	No response (safety filter)	False
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 with regards to taking efavirenz? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 with regards to taking efavirenz? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate efavirenz with standard dosing (600 mg/day)	Unchanged	No response (safety filter)	False
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Alter dose	False
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Alter dose	False
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking enflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking escitalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	Avoid	No response (safety filter)	False
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking escitalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Avoid	Alter dose	False
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking escitalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Avoid	Alter dose	False
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking escitalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose	Unchanged	Unchanged	True
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking escitalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking escitalopram? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Unchanged	Alter dose	False
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking fluorouracil? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	Alter dose	Alter Dose	False
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking fluorouracil? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	Alter dose	Alter dose	True
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking fluorouracil? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Avoid	Avoid	True
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for DPYD with regards to taking fluorouracil? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.	Avoid	Avoid	True
fluorouracil	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking fluorouracil? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	Unchanged	Alter dose	False
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking flurbiprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Alter dose	Avoid	False
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking flurbiprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Alter dose	Alter dose	True
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking flurbiprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking flurbiprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking flurbiprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.	Alter dose	Alter dose	True
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Avoid	False
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Avoid	False
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Avoid	Avoid	True
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 and Poor Function for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Avoid	Alter dose	False
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Avoid	Alter dose	False
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Increased Function for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.	Unchanged	Alter dose	False
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.	Unchanged	Alter dose	False
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	Unchanged	Alter dose	False
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking fluvoxamine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25-50% lower starting dose and slower titration schedule as compared to normal metabolizers or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Alter dose	Avoid	False
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking fluvoxamine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking fluvoxamine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking fluvoxamine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation due to lack of evidence	Unchanged	Avoid	False
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Alter dose	No response (safety filter)	False
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Alter dose	Unchanged	False
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Alter dose	Unchanged	False
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Avoid	Avoid	True
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Avoid	Avoid	True
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Avoid	Avoid	True
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Unchanged	Unchanged	True
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Unchanged	Avoid	False
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Unchanged	Avoid	False
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking furazolidone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
furazolidone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking furazolidone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking furazolidone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Alter dose	False
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Avoid	False
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Unchanged	True
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking glyburide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
glyburide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking glyburide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking glyburide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Unchanged	True
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking hydrocodone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Unchanged	Avoid	False
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking hydrocodone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	Unchanged	No response (safety filter)	False
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking hydrocodone? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use hydrocodone label recommended age- or weight-specific dosing.	Unchanged	No response (safety filter)	False
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking hydroxychloroquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Alter dose	False
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking hydroxychloroquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking hydroxychloroquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	No response (safety filter)	False
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking ibuprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Alter dose	Alter dose	True
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking ibuprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Alter dose	Avoid	False
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking ibuprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking ibuprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking ibuprofen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	No response (safety filter)	False
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Alter dose	No response (safety filter)	False
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	Alter dose	True
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Avoid	Avoid	True
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Avoid	No response (safety filter)	False
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Avoid	Alter dose	False
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	No response (safety filter)	False
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	No response (safety filter)	False
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Avoid	False
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Alter dose	False
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking isoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Unchanged	True
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Unchanged	True
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor non-responsive in CF patients for CFTR with regards to taking ivacaftor? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Ivacaftor is not recommended	Avoid	Avoid	True
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor responsive in CF patients for CFTR with regards to taking ivacaftor? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use ivacaftor according to the product label	Unchanged	Unchanged	True
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Avoid	True
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Unchanged	True
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Alter dose	Alter dose	True
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy."	Alter dose	Alter dose	True
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking lansoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Alter dose	Alter dose	True
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking lansoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking lornoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Alter dose	Avoid	False
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking lornoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.	Alter dose	Avoid	False
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking lornoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking lornoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking lornoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking lovastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.	Avoid	Alter dose	False
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking lovastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.	Avoid	Avoid	True
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking lovastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Avoid	Avoid	True
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking lovastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Unchanged	True
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking lovastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Avoid	False
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking lovastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking mafenide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
mafenide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking mafenide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	No response (safety filter)	False
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking mafenide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking meloxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Alter dose	Alter dose	True
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking meloxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Avoid	Alter dose	False
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking meloxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Avoid	Alter dose	False
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking meloxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	No response (safety filter)	False
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking meloxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	No response (safety filter)	False
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking meloxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Alter dose	Alter dose	True
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Alter dose	Alter dose	True
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Alter dose	Alter dose	True
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Unchanged	Alter dose	False
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Unchanged	Unchanged	True
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Indeterminate for NUDT15 with regards to taking mercaptopurine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Unchanged	Alter dose	False
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	No response (safety filter)	False
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking methoxyflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking methylene blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking methylene blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
methylene blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking methylene blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid ased on G6PD status	Unchanged	Unchanged	True
methylene blue	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking methylene blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	No response (safety filter)	False
methylene blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking methylene blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nalidixic acid? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nalidixic acid? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Alter dose	False
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nalidixic acid? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
neomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Avoid	True
neomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
neomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Avoid	False
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Avoid	True
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Unchanged	True
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nitrofurantoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid	Avoid	Avoid	True
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nitrofurantoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use at standard doses with caution and with close monitoring for anemia	Unchanged	Avoid	False
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nitrofurantoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Unchanged	True
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nitrofurantoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking norfloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
norfloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking norfloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Alter dose	False
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking norfloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Alter dose	Alter dose	True
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Alter dose	Alter dose	True
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Alter dose	Alter dose	True
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Avoid	Alter dose	False
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Avoid	Alter dose	False
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	Avoid	Alter dose	False
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose	Unchanged	Alter dose	False
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose	Unchanged	Alter dose	False
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking nortriptyline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ofloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
ofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ofloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ofloxacin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Alter dose	Unchanged	False
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking omeprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Alter dose	Avoid	False
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking omeprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Alter dose	Alter dose	True
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking omeprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking ondansetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Avoid	Alter dose	False
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking ondansetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Avoid	Alter dose	False
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking ondansetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Avoid	Avoid	True
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking ondansetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Unchanged	Avoid	False
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking ondansetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking ondansetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Unchanged	Avoid	False
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is oxcarbazepine-naïve, do not use oxcarbazepine.	Avoid	Avoid	True
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use oxcarbazepine per standard dosing guidelines.	Unchanged	Avoid	False
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use oxcarbazepine per standard dosing guidelines.	Unchanged	Unchanged	True
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.	Unchanged	Avoid	False
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Alter dose	Alter dose	True
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking pantoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Alter dose	Alter dose	True
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking pantoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Alter dose	Alter dose	True
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking pantoprazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Alter dose	False
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Avoid	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.	Alter dose	No response (safety filter)	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to normal metabolizers.	Alter dose	No response (safety filter)	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.	Alter dose	No response (safety filter)	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6.	Avoid	No response (safety filter)	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6.	Avoid	No response (safety filter)	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6.	Avoid	No response (safety filter)	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose	Unchanged	Avoid	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose	Unchanged	No response (safety filter)	False
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking paroxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Unchanged	True
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking pegloticase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking pegloticase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
pegloticase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking pegloticase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
pegloticase	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking pegloticase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
pegloticase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking pegloticase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Alter dose	False
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking phenazopyridine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking phenazopyridine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking phenazopyridine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Unchanged	True
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Alter dose	Avoid	False
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Alter dose	Unchanged	False
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	Alter dose	Unchanged	False
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Avoid	Avoid	True
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Avoid	Avoid	True
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	Avoid	Avoid	True
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Unchanged	Avoid	False
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	Unchanged	Unchanged	True
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	Unchanged	Avoid	False
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking piroxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Avoid	Alter dose	False
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking piroxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Avoid	Alter dose	False
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking piroxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Avoid	Avoid	True
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking piroxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Avoid	False
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking piroxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	Alter dose	False
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking piroxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pitavastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Alter dose	True
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking pitavastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Alter dose	True
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking pitavastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).	Alter dose	Alter dose	True
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pitavastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Alter dose	False
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pitavastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Unchanged	True
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pitavastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Alter dose	False
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Avoid	False
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking pravastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40mg.	Alter dose	Avoid	False
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pravastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Unchanged	True
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pravastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Avoid	False
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pravastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Unchanged	Alter dose	False
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking primaquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid primaquine	Avoid	Avoid	True
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking primaquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.	Avoid	Avoid	True
primaquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking primaquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
primaquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking primaquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Alter dose	False
primaquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking primaquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	No response (safety filter)	False
quinine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking quinine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
quinine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking quinine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
quinine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking quinine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking rasburicase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking rasburicase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
rasburicase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking rasburicase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
rasburicase	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking rasburicase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
rasburicase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking rasburicase? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Avoid	True
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Unchanged	True
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.	Alter dose	Alter dose	True
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Alter dose	True
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Poor Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	Alter dose	Avoid	False
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	Unchanged	Alter dose	False
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	Unchanged	Alter dose	False
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Possible Decreased Function for SLCO1B1 with regards to taking rosuvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	Unchanged	Alter dose	False
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Normal Metabolizer for CYP2C19 with regards to taking sertraline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.	Alter dose	Alter dose	True
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers	Alter dose	Alter dose	True
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Alter dose	Alter dose	True
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Poor Metabolizer for CYP2C19 with regards to taking sertraline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.	Avoid	Alter dose	False
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2B6 and Likely Poor Metabolizer for CYP2C19 with regards to taking sertraline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.	Avoid	Alter dose	False
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.	Unchanged	Unchanged	True
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.	Unchanged	Alter dose	False
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2B6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking sertraline? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Unchanged	Alter dose	False
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Unchanged	False
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Unchanged	True
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Unchanged	True
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Unchanged	True
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking simvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.	Avoid	Alter dose	False
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for SLCO1B1 with regards to taking simvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.	Avoid	Avoid	True
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Poor Function for SLCO1B1 with regards to taking simvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).	Avoid	Alter dose	False
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking simvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Avoid	False
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking simvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	Unchanged	Unchanged	True
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking simvastatin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Avoid	True
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Avoid	False
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Avoid	False
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	Avoid	Avoid	True
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Avoid	False
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking succinylcholine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Unchanged	True
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	Unchanged	Alter dose	False
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadiazine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadiazine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadiazine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadimidine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadimidine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadimidine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	No response (safety filter)	False
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfamethoxazole / trimethoprim? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfamethoxazole / trimethoprim? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfamethoxazole / trimethoprim? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfanilamide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfanilamide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfanilamide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfasalazine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfasalazine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfasalazine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfisoxazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfisoxazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfisoxazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Normal Metabolizer for CYP3A5 with regards to taking tacrolimus? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	Alter dose	Alter dose	True
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	Alter dose	Alter dose	True
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	Alter dose	Alter dose	True
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Indeterminate for CYP3A5 with regards to taking tacrolimus? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Poor Metabolizer for CYP3A5 with regards to taking tacrolimus? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.	Unchanged	Alter dose	False
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tafenoquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tafenoquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
tafenoquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tafenoquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Unchanged	True
tafenoquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tafenoquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
tafenoquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tafenoquine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tamoxifen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Avoid	Alter dose	False
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking tamoxifen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.	Avoid	Alter dose	False
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tamoxifen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	Avoid	Alter dose	False
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tamoxifen? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking tenoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Avoid	No response (safety filter)	False
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.5 for CYP2C9 with regards to taking tenoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Avoid	Unchanged	False
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking tenoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	Avoid	Avoid	True
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking tenoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	No response (safety filter)	False
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking tenoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	No response (safety filter)	False
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking tenoxicam? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	Unchanged	No response (safety filter)	False
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Alter dose	No response (safety filter)	False
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	Alter dose	No response (safety filter)	False
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	Alter dose	No response (safety filter)	False
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Unchanged	No response (safety filter)	False
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Unchanged	No response (safety filter)	False
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Indeterminate for TPMT and Indeterminate for NUDT15 with regards to taking thioguanine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.	Unchanged	No response (safety filter)	False
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Avoid	Alter dose	False
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Alter dose	False
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Unchanged	Unchanged	True
tolbutamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tolbutamide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status	Unchanged	Avoid	False
tolbutamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tolbutamide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tolbutamide? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking toluidine blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking toluidine blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid use	Avoid	Avoid	True
toluidine blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking toluidine blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid ased on G6PD status	Unchanged	Unchanged	True
toluidine blue	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking toluidine blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
toluidine blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking toluidine blue? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Avoid	False
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tramadol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Avoid	Avoid	True
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking tramadol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Avoid	No response (safety filter)	False
tramadol	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking tramadol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.	Avoid	No response (safety filter)	False
tramadol	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tramadol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	No response (safety filter)	False
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tramadol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	Unchanged	No response (safety filter)	False
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking tramadol? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use tramadol label recommended age- or weight-specific dosing.	Unchanged	No response (safety filter)	False
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	Alter dose	True
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Alter dose	Unchanged	False
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Alter dose	Alter dose	True
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Avoid	Alter dose	False
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Likely Poor Metabolizer for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Avoid	Avoid	True
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Avoid	Alter dose	False
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and Likely Intermediate Metabolizer for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 and Indeterminate for CYP2C19 with regards to taking trimipramine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No recommendation	Unchanged	Alter dose	False
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tropisetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Avoid	Avoid	True
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tropisetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Avoid	Avoid	True
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking tropisetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Avoid	Avoid	True
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking tropisetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tropisetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Unchanged	True
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking tropisetron? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	Unchanged	Avoid	False
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking venlafaxine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Avoid	Alter dose	False
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking venlafaxine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Unchanged	Alter dose	False
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking venlafaxine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	Unchanged	Alter dose	False
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking venlafaxine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	Alter dose	False
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin c? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Avoid	False
vitamin c	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin c? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Unchanged	True
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin c? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Alter dose	False
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin k? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	No reason to avoid based on G6PD status at standard doses	Unchanged	Unchanged	True
vitamin k	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin k? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Unchanged	Unchanged	True
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin k? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Unchanged	Avoid	False
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.	Avoid	Alter dose	False
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking voriconazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	Avoid	Alter dose	False
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking voriconazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	Avoid	Avoid	True
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended standard of care dosing	Unchanged	Alter dose	False
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking voriconazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended standard of care dosing. Use therapeutic drug monitoring to titrate dose to therapeutic trough concentrations.	Unchanged	Alter dose	False
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking voriconazole? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended standard of care dosing	Unchanged	Alter dose	False
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking vortioxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate 50% of starting dose (e.g., 5 mg) and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Alter dose	No response (safety filter)	False
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking vortioxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Avoid	Avoid	True
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking vortioxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Avoid	No response (safety filter)	False
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 with regards to taking vortioxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	Avoid	No response (safety filter)	False
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking vortioxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	No response (safety filter)	False
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking vortioxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	No response (safety filter)	False
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking vortioxetine? Please respond with just 'Avoid' if the guidance is to avoid the drug or take an alternate drug, 'Alter dose' if the guideline is to raise, lower, or start with a specific dose, or 'Unchanged', if there are no clinical recommendations or there is no deviation from standard care for this phenotype and drug.	Initiate therapy with recommended starting dose.	Unchanged	No response (safety filter)	False
